ISA Pharmaceuticals B.V., an Oegstgeest, The Netherlands-based clinical-stage immunotherapy company, closed a €26m funding round.
Backers included new investors Invest-NL and existing investors including Regeneron.
The company intends to use the funds to advance the lead product ISA101b towards first marketing authorization as well as to broaden the clinical pipeline of immunotherapies based on the Synthetic Long Peptide (SLP®) platform technology.
Led by Gerben Moolhuizen, CEO, ISA Pharmaceuticals is an immunotherapy company developing treatments for various cancers and infectious diseases. Its lead asset ISA101b is in late-stage clinical trials for human papillomavirus type 16 (HPV16) induced cancers in a collaboration with US pharmaceutical company Regeneron. Other assets are in preclinical stage development and include immunotherapies to treat patients that suffer from chronic hepatitis B infections (HBV), cancers that over-express PRAME, cancers caused by other HPV types than HPV16, and SARS-CoV2 infections, the virus that causes COVID-19.
FinSMEs
13/07/2021